alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 14,851–14,875 of 27,146 studies marked Peer-reviewed (page 595 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Immune–proteo–metabolomic changes link to Aβ and tau pathology in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2026-04-01

Thirteen differentially expressed CSF proteins in A+T+ individuals correlated positively with tryptophan metabolites and pyroglutamate, and negatively with regulatory T cells, isobutyrate, and dendritic cells. 4 key findings →

Participants: 19 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

[18F]Florzolotau PET for the Differential Diagnosis of Parkinsonism in Patients with Suspected 4-Repeat Tauopathies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Nuclear Medicine 2025-04-17

The 4R-like pattern was more prevalent and more strongly expressed (84.3%, mean score, 2.0 ± 1.1) in patients with a consensus diagnosis of PSP/CBD (joint diagnostic group of clinically likely 4R tauopathies) than in all other groups (11.6%, 0.26 ± 0.75, P < 0.0001). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma vesicle-associated membrane protein 2 and glial fibrillary acidic protein associate with synaptic density in older adults without dementia

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain Communications 2025-01-01

The study population demonstrated limited PET-based amyloid-β and tau pathology, which did not associate with any of the investigated plasma biomarkers. 5 key findings →

Design: cross-sectional Participants: 49 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Acta Neuropathologica Communications 2025-02-15

Using the RGC marker ribonucleic acid binding protein with multiple splicing (RBPMS) and Nissl staining, we found a 46–56% reduction in RBPMS + RGCs and Nissl + neurons in the ganglion cell layer (GCL) of MCI and AD retinas ( P < 0.05–0.001). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journal of Experimental Medicine 2025-08-05

Alzheimer's disease (AD), the most common cause of dementia, is characterized by the accumulation of amyloid-β (Aβ) in senile plaques and abnormally hyperphosphorylated tau proteins in neurofibrillary tangles. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s Research & Therapy 2025-05-22

CSF and plasma SNAP25 were positively correlated, but no correlation was observed for VAMP2 in these matrices. 5 key findings →

Participants: 80 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Communications Biology 2025-01-14

Aggregation of microtubule-associated tau protein is a distinct hallmark of several neurodegenerative disorders such as Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and progressive supranuclear palsy (PSP). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

α-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in Neuroscience 2025-03-27

Neurodegenerative diseases are characterized by protein aggregation and overlapping pathologies, challenging traditional classifications and highlighting shared underlying mechanisms. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying RAGE inhibitors as potential therapeutics for Alzheimer’s disease via integrated in-silico approaches

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Scientific Reports 2025-05-22

Alzheimer's disease is a neurodegenerative disorder characterized by two hallmarks: amyloid beta plaques and neurofibrillary tangles. 2 key findings →

Participants: 708,580 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cognitive training reorganizes lateralization of fronto-parietal network in vascular cognitive impairment

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Brain Communications 2025-01-01

These findings suggest that subcortical VCIND modifies the relationship between FPN lateralization and cognitive functions, rather than altering the lateralization pattern itself. 1 key finding →

Participants: 30 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Can a Mediterranean diet prevent cognitive decline?

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2025-11-11

Current evidence suggests a potential for the Mediterranean diet to prevent cognitive decline, largely supported by observational studies, although randomized controlled trials show mixed results. 1 key finding →

Evidence: high

Full summary, score breakdown and related studies → Original source

Dietary Patterns and Risk of Age-Related Cognitive Decline and Dementia: Enthusiasm Before Evidence?

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Innovation in Aging 2025-12-01

When systematically reviewed using the USDA Nutrition Evidence Systematic Review method and an a priori established protocol, a common theme emerged: diets characterized by higher consumption of vegetables, fruits, legumes, nuts, fish, seafood, and unsaturated vegetable oils, alongside lower intake of red and processed meats and sugar-sweetened beverages, are consistently associated with a reduced risk of cognitive decline and dementia. 2 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Overactive bladder medications and risk of emergency hospital admissions with delirium in adults without dementia: self-controlled case series

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Age and Ageing 2025-08-29

The risk of delirium admissions was elevated for the first 1-30 days of prescriptions [IRR 1.54 (95% CI 1.30-1.82) for men, 1.44 (1.22-1.70) for women] and whilst reducing over time for women [1.10 (0.94-1.29) for 91-365 days of prescriptions], it remained elevated for men [1.38 (1.17-1.64)]. 5 key findings →

Participants: 293 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of cognitive morbidity including delirium in 51,202 emergency hospital admissions across 29 medical and surgical specialties in ORCHARD-EPR: a cross-sectional study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. EClinicalMedicine 2025-11-24

Among 51,202 admissions (mean/SD age = 82/7 years), any cognitive morbidity was present in 18,225 (35.6%, 95% CI 35.2-36.0%): delirium occurred in 24.0% (n = 12,289, of which 14.3% (n = 7332) had delirium only and 9.7% (n = 4957) had delirium + dementia) dementia only in 8.7%, (n = 4450), AMTS <8 in 2.9% (n = 1486). 5 key findings →

Participants: 12,289 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Feasibility, acceptability, and preliminary efficacy protocol of an intervention for caregivers of hospice patients living with dementia: A pilot randomized control trial

✓ Peer-reviewed alzhub usefulness score 45 out of 100. PLoS ONE 2025-11-03

We have enrolled 29 clinicians and 53 FCPs and aim to have 24 clinicians matched with 96 FCPs (N = 120) to complete the intervention. 3 key findings →

Participants: 120 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Physical and psychosocial benefits of an interdisciplinary end-of-life care model for older adults in residential care homes in Hong Kong

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International Psychogeriatrics 2026-01-01

Pre-post evaluations revealed significant reductions in physical symptoms, psychosocial-spiritual distresses and information insufficiency of patients in the first three months of service. 4 key findings →

Participants: 567 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Virtual, Nurse-Led Early Primary Palliative Care Intervention (ELICIT) for Community-Dwelling Older Adults With Cognitive Impairment: Protocol for a Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 45 out of 100. JMIR Research Protocols 2025-12-24

As of October 2025, we have recruited 200 participants. 4 key findings →

Participants: 200 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed